Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells

详细信息    查看全文

• 作者：Samaya R. Krishnan (1) (2)
  Binoj C. Nair (2)
  Gangadhara R. Sareddy (2)
  Sudipa Saha Roy (2)
  Mohan Natarajan (3)
  Takayoshi Suzuki (4)
  Yan Peng (5)
  Ganesh Raj (6)
  Ratna K. Vadlamudi (2) (7)
  
  1. Department of Cellular and Structural Biology ; UTHSCSA ; 7703 Floyd Curl Drive ; San Antonio ; TX ; 78229 ; USA
  2. Department of Obstetrics and Gynecology ; UTHSCSA ; 7703 Floyd Curl Drive ; San Antonio ; TX ; 78229 ; USA
  3. Department of Pathology ; UTHSCSA ; 7703 Floyd Curl Drive ; San Antonio ; TX ; 78229 ; USA
  4. Graduate School of Medical Science ; Kyoto Prefectural University of Medicine ; 1-5 Shimogamohangi-Cho ; Sakyo-Ku ; Kyoto ; 606-0823 ; Japan
  5. Department of Pathology ; UT Southwestern Medical Center ; 5323 Harry Hines Blvd ; Dallas ; TX ; 75390 ; USA
  6. Department of Urology ; UT Southwestern Medical Center ; 5323 Harry Hines Blvd ; Dallas ; TX ; 75390 ; USA
  7. Cancer Therapy and Research Center ; UTHSCSA ; 7703 Floyd Curl Drive ; San Antonio ; TX ; 78229 ; USA
  
• 关键词：PELP1 ; p53 ; DNA damage response ; Oncogene ; Coregulator ; E2F1 ; TNBC
• 刊名：Breast Cancer Research and Treatment
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：150
• 期：3
• 页码：487-499
• 全文大小：1,593 KB
• 参考文献：1. Bauer, KR, Brown, M, Cress, RD, Parise, CA, Caggiano, V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: pp. 1721-1728 CrossRef
  2. Dent, R, Trudeau, M, Pritchard, KI (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: pp. 4429-4434 CrossRef
  3. Liedtke, C, Mazouni, C, Hess, KR (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: pp. 1275-1281 CrossRef
  4. Sorlie, T, Perou, CM, Tibshirani, R (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U.S.A 98: pp. 10869-10874 CrossRef
  5. Lehmann, BD, Bauer, JA, Chen, X (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121: pp. 2750-2767 CrossRef
  6. Shah, SP, Roth, A, Goya, R (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: pp. 395-399
  7. Wright, JD, Lim, C (2007) Mechanism of DNA-binding loss upon single-point mutation in p53. J Biosci 32: pp. 827-839 CrossRef
  8. Oren, M, Rotter, V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: pp. a001107 CrossRef
  9. Xu, J, Reumers, J, Couceiro, JR (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7: pp. 285-295 CrossRef
  10. Di, AS, Strano, S, Emiliozzi, V (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: pp. 191-202 CrossRef
  11. DeGregori, J, Johnson, DG (2006) Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis. Curr Mol Med 6: pp. 739-748
  12. Engelmann, D, Putzer, BM (2012) The dark side of E2F1: in transit beyond apoptosis. Cancer Res 72: pp. 571-575 CrossRef
  13. Phillips, AC, Vousden, KH (2001) E2F-1 induced apoptosis. Apoptosis 6: pp. 173-182 CrossRef
  14. Lin, WC, Lin, FT, Nevins, JR (2001) Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev 15: pp. 1833-1844
  15. Pediconi, N, Ianari, A, Costanzo, A (2003) Differential regulation of E2F1 apoptotic target genes in response to DNA damage. Nat Cell Biol 5: pp. 552-558 CrossRef
  16. Xie, Q, Bai, Y, Wu, J (2011) Methylation-mediated regulation of E2F1 in DNA damage-induced cell death. J Recept Signal Transduction Res 31: pp. 139-146
  17. Hershko, T, Ginsberg, D (2004) Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 279: pp. 8627-8634 CrossRef
  18. Tonsing-Carter, E, Shannon, HE, Bailey, BJ, Mayo, LD, Pollok, KE (2013) Blockade of MDM2-mediated signaling in context of DNA damage increases E2F1 expression and enhances cell death in triple-negative breast cancer cells. Cancer Research. 279: pp. 8627-8634
  19. Gonugunta, VK, Miao, L, Sareddy, GR (2014) The social network of PELP1 and its implications in breast and prostate cancers. Endocr Relat Cancer 21: pp. T79-T86 CrossRef
  20. Girard, BJ, Daniel, AR, Lange, CA, Ostrander, JH (2014) PELP1: a review of PELP1 interactions, signaling, and biology. Mol Cell Endocrinol 382: pp. 642-651 CrossRef
  21. Habashy, HO, Powe, DG, Rakha, EA (2010) The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat 120: pp. 603-612 CrossRef
  22. Roy, S, Chakravarty, D, Cortez, V (2012) Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res 10: pp. 25-33 CrossRef
  23. Nair, BC, Nair, SS, Chakravarty, D (2010) Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res 70: pp. 7166-7175 CrossRef
  24. Nair, BC, Krishnan, SR, Sareddy, GR (2014) Proline, glutamic acid and leucine-rich protein-1 is essential for optimal p53-mediated DNA damage response. Cell Death Differ 21: pp. 1409-1418 CrossRef
  25. Mann, M, Cortez, V, Vadlamudi, R (2013) PELP1 oncogenic functions involve CARM1 regulation. Carcinogenesis 34: pp. 1468-1475 CrossRef
  26. Bararia, D, Trivedi, AK, Zada, AA (2008) Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia 22: pp. 800-807 CrossRef
  27. Bartek, J, Iggo, R, Gannon, J, Lane, DP (1990) Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: pp. 893-899
  28. Nigro, JM, Baker, SJ, Preisinger, AC (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: pp. 705-708 CrossRef
  29. Mann, M, Cortez, V, Vadlamudi, RK (2011) Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) 3: pp. 1691-1707 CrossRef
  30. Sterner, DE, Berger, SL (2000) Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64: pp. 435-459 CrossRef
  31. Bossi, G, Lapi, E, Strano, S (2006) Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 25: pp. 304-309
  32. Lim, LY, Vidnovic, N, Ellisen, LW, Leong, CO (2009) Mutant p53 mediates survival of breast cancer cells. Br J Cancer 101: pp. 1606-1612 CrossRef
  33. Kontaki, H, Talianidis, I (2010) Lysine methylation regulates E2F1-induced cell death. Mol Cell 39: pp. 152-160 CrossRef
  34. Nair, SS, Nair, BC, Cortez, V (2010) PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep 11: pp. 438-444 CrossRef
  35. Ueda, R, Suzuki, T, Mino, K (2009) Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc 131: pp. 17536-17537 CrossRef
  36. Boohaker, RJ, Cui, X, Stackhouse, M, Xu, B (2013) ATM-mediated Snail Serine 100 phosphorylation regulates cellular radiosensitivity. Radiother Oncol 108: pp. 403-408 CrossRef
  37. Sun, M, Guo, X, Qian, X (2012) Activation of the ATM-Snail pathway promotes breast cancer metastasis. J Mol Cell Biol 4: pp. 304-315 CrossRef
  38. Bertheau, P, Lehmann-Che, J, Varna, M (2013) p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast 22: pp. S27-S29 CrossRef
  39. Dobes, P, Podhorec, J, Coufal, O (2014) Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep 32: pp. 1695-1702
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7217

文摘

Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, occurs in younger women and is associated with poor prognosis. Gain-of-function mutations in TP53 are a frequent occurrence in TNBC and have been demonstrated to repress apoptosis and up-regulate cell cycle progression. Even though TNBC responds to initial chemotherapy, resistance to chemotherapy develops and is a major clinical problem. Tumor recurrence eventually occurs and most patients die from their disease. An urgent need exists to identify molecular-targeted therapies that can enhance chemotherapy response. In the present study, we report that targeting PELP1, an oncogenic co-regulator molecule, could enhance the chemotherapeutic response of TNBC through the inhibition of cell cycle progression and activation of apoptosis. We demonstrate that PELP1 interacts with MTp53, regulates its recruitment, and alters epigenetic marks at the target gene promoters. PELP1 knockdown reduced MTp53 target gene expression, resulting in decreased cell survival and increased apoptosis upon genotoxic stress. Mechanistic studies revealed that PELP1 depletion contributes to increased stability of E2F1, a transcription factor that regulates both cell cycle and apoptosis in a context-dependent manner. Further, PELP1 regulates E2F1 stability in a KDM1A-dependent manner, and PELP1 phosphorylation at the S1033 residue plays an important role in mediating its oncogenic functions in TNBC cells. Accordingly, depletion of PELP1 increased the expression of E2F1 target genes and reduced TNBC cell survival in response to genotoxic agents. PELP1 phosphorylation was significantly greater in the TNBC tumors than in the other subtypes of breast cancer and in the normal tissues. These findings suggest that PELP1 is an important molecular target in TNBC, and that PELP1-targeted therapies may enhance response to chemotherapies.